Kirk A. Christoffersen
Corporate Officer/Principal bei FIBROGEN, INC.
Profil
Kirk A.
Christoffersen is currently the Chief Business Officer at FibroGen, Inc. He previously worked as the Vice President of Corporate Development at GlobeImmune, Inc. and as the Senior VP of Corporate & Business Development at Compugen Ltd.
He also held positions at Gilead Sciences, Inc. and OSI Pharmaceuticals, Inc. Additionally, he worked as the Chief Business Officer at Arch Oncology, Inc. and as a Principal at Sirna Therapeutics, Inc. Christoffersen received his undergraduate degree from the University of Michigan and his MBA from Daniels College of Business.
Aktive Positionen von Kirk A. Christoffersen
| Unternehmen | Position | Beginn |
|---|---|---|
| FIBROGEN, INC. | Corporate Officer/Principal | 01.11.2020 |
Ehemalige bekannte Positionen von Kirk A. Christoffersen
| Unternehmen | Position | Ende |
|---|---|---|
| COMPUGEN LTD. | Corporate Officer/Principal | 08.01.2020 |
| GLOBEIMMUNE, INC. | Corporate Officer/Principal | 03.08.2015 |
| OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2004 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.01.2002 |
Arch Oncology, Inc.
 Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Corporate Officer/Principal | - |
Ausbildung von Kirk A. Christoffersen
| University of Michigan | Undergraduate Degree |
| Daniels College of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| GLOBEIMMUNE, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| COMPUGEN LTD. | Health Technology |
| FIBROGEN, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Commercial Services |
